What Racol Treats: Main Uses and Benefits

Racol is commonly used for managing acute pain that may be severe enough to require additional symptomatic support, particularly when simpler treatments are inadequate. It is intended for the management of acute, moderate to moderately severe pain.

This combination is applied in addressing groups of symptoms that may become intense or disruptive, helping to address pain that creates noticeable physiological strain. It is relevant for easing challenging symptoms associated with post-operative discomfort, pain following injuries, and the persistent manifestations of chronic conditions like osteoarthritis and chronic lower back pain. It is generally used in situations where symptoms interfere with daily functioning and require a comprehensive approach to symptomatic support.

Quick Fact: Relief for Heightened Symptoms

The medication is utilized in clinical settings marked by increased discomfort or tension, such as phases of acute escalation or periods of recurrence. It offers symptomatic relief that helps improve day-to-day comfort.

Official Eligibility and Contraindications for Racol

Note: There are no official governmental regulatory documents (such as FDA Prescribing Information or EMA Summary of Product Characteristics) that describe the eligibility, contraindications, or specific population rules for a product named "Racol." Therefore, the following information cannot be provided from authoritative regulatory sources.

If Racol were an approved product, its eligibility profile would be strictly defined in its official labeling, including formal contraindications and restrictions for specific populations.

Category	Regulatory Status (Not Applicable)
Populations for whom use is contraindicated	Not documented in regulatory sources.
Age-related eligibility rules	Use status in pediatric and geriatric populations is not established in regulatory documents.
Condition-specific rules	Eligibility based on conditions like renal or hepatic impairment is not defined in official labeling.
Pregnancy and lactation status	No official eligibility classification (e.g., contraindicated, not recommended) is available.

Eligibility for any approved medicine is determined by regulatory bodies based on a comprehensive review of clinical trial data. The lack of an official eligibility map means there is no authoritative, government-mandated information on who should or should not use this medicine.

Racol Interactions with other medicines and products

Note on Product Identity: Regulatory information for a product named Racol is primarily available for a semi-digested enteral nutritional formula (a medical food product), not a conventional drug. This product is a combination of protein, lipid, carbohydrate, electrolytes, and vitamins. The interactions listed below are based on the standard regulatory profile for its use as a nutritional support.

---

• Interactions with Conventional Medicines

The product is an enteral formula; therefore, conventional drug-to-drug pharmacokinetic interactions (e.g., enzyme inhibition or induction) are generally not applicable. However, it may interact with oral medicinal products by affecting their absorption, which may require timing separation during administration. For instance, the use of other medicinal products should be carefully monitored when co-administered via the same enteral feeding route.

• Condition-Specific Interactions

Use of this product requires caution and monitoring in patients with pre-existing conditions that affect metabolism or tolerance. This includes individuals with known allergies to milk protein, as well as those with compromised intestinal, hepatic, or renal function. Furthermore, patients with abnormal glucose metabolism, such as diabetes, require careful blood sugar monitoring due to the carbohydrate content.

Racol functions through a synergistic multimodal mechanism that modulates nociceptive signaling across three distinct pathways in the Central Nervous System (CNS). The action involves simultaneous operation of the two components to modulate signal transmission and elevate the central sensory threshold.

---

Dual Modulation of Central Opioid and Monoamine Pathways

This domain focuses on the Tramadol component, which engages both mu-opioid receptors and neurotransmitter transporters. The active metabolite binds to the mu-opioid receptor, reducing the ability of nerve cells to transmit signals, while the parent drug inhibits the reuptake of Serotonin and Norepinephrine. This combined action enhances the activity of the descending inhibitory pain pathway, resulting in the attenuation of signal transmission at the level of the spinal cord.

---

Non-Opioid Targeting of Central Prostaglandins

This domain focuses on the Acetaminophen component, which modulates the Cyclooxygenase ( COX) enzyme system almost exclusively in the CNS. By inhibiting the synthesis of prostaglandin E2 ( PGE2) in the brain, this mechanism elevates the central sensory threshold. This central non-opioid effect complements Tramadol’s transmission-blocking mechanism, which forms the basis of the combined physiological effect.

Racol is administered exclusively through the oral route as a fixed-dose tablet containing 37.5 mg of tramadol hydrochloride and 325 mg of acetaminophen. The standard adult regimen begins with an initial dose of two tablets. This dosage is typically maintained, with subsequent two-tablet doses taken as needed for pain relief, provided there is a mandatory interval of at least four to six hours between administrations.

The total daily intake must not exceed eight tablets (equivalent to 300 mg tramadol and 2,600 mg acetaminophen) within a 24-hour period. As an administration guideline, the tablet may be swallowed whole without regard to meals, but it must not be broken, crushed, or chewed. The use of this fixed combination is generally restricted to the short-term management of acute pain, typically limited to a duration of five days or less.

Specific dose adjustments are required for certain populations. For patients diagnosed with severe renal impairment (creatinine clearance less than 30 mL/min), the dosing interval must be extended to a minimum of 12 hours, and the daily maximum dose must be reduced. Furthermore, Racol is not for use in children under 12 years of age and is not recommended for patients with severe hepatic impairment. Patients must not use other products containing either tramadol or acetaminophen concurrently to prevent exceeding the maximum daily dose.

Research Evidence / Overview of Studies for Racol

Evidence for Use in Acute Pain

The research that included this medicine in studies of acute pain—such as pain following a procedure or injury—primarily relies on short-term, randomized controlled trials (RCTs). These are studies where patients experiencing acute episodes of physical discomfort are temporarily assigned to receive either the fixed-dose combination, a placebo (an inactive control), or one of the active ingredients alone.

Studies explored outcomes related to episodic or acute changes in symptoms. Findings describe patterns observed in the studies where the fixed combination was associated with a pattern of higher total pain relief scores in the observed populations compared to either of the two ingredients used individually. Research explored if the combination was associated with a pattern of faster onset in the time it took to report initial measured pain relief. Follow-up durations were limited, meaning the evidence is focused solely on the immediate, acute phase.

---

Evidence for Use in Chronic Lower Back Pain

Research examining Racol in chronic conditions involves intermediate-duration randomized trials. These studies were applied in research contexts involving fluctuating or unstable symptoms in patients with chronic lower back pain. Research explored patient-reported outcomes, such as those measured by disability and activity level scales, in addition to pain intensity scores.

Studies monitored how patient-reported symptoms evolved over periods typically ranging from one to three months. Trials reported that the mean pain intensity measurements differed between the combination group and the placebo group over the study period. Studies documented a pattern where functional status and disability scores varied in the observed populations over the three-month study duration.

---

What Is Still Uncertain About Racol's Research

The overall evidence landscape has several limitations that are highlighted in regulatory and scientific reviews. Research is ongoing, but certainty remains low in several key areas.

Specifically, there is limited information for long-term outcomes and functional status beyond the intermediate-duration trials. Comparative evidence is lacking for many other standard pain treatments. Furthermore, the results apply only to the populations studied (primarily adults with acute or non-complex chronic pain), meaning data for certain groups (like children, older adults, or those with comorbidities) remain insufficient for broad conclusions.

Key Studies & References

1. Tramadol hydrochloride/acetaminophen combination for the relief of acute pain
2. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study
3. Tramadol and Acetaminophen Combination for Chronic non-Cancer Pain

Common questions about Racol (FAQ)

---

Q: Does Racol start working immediately after the first use?

Official data on the tramadol component indicates that pain-relieving effects usually begin within one hour of ingestion. The maximum effect is typically reached within two to four hours after the dose is taken. This suggests the medicine is not considered to start working immediately.

---

Q: What is the typical timeframe before noticing an effect from Racol?

According to regulatory documents, the onset of pain relief usually begins within one hour after taking the tablet. This timeframe is based on the absorption and effect of the active ingredients within the body.

---

Q: If I miss a dose of Racol, what should I do?

Regulatory guidance describes skipping the missed dose and returning to the regular dosing schedule. The product labeling advises against taking double or extra doses to make up for the one that was missed.

---

Q: Can Racol be used by teenagers or older adults?

Official warnings state the medicine is contraindicated in children younger than 12 years of age. For adolescents aged 12 to 18, its use is avoided if they have certain risk factors for breathing problems. Use in older adults also requires caution due to a potential increase in opioid-related effects.

---

Q: Does Racol affect sleep patterns?

Yes. Official sources list somnolence (drowsiness) as a Very Common side effect. Other effects reported in the prescribing information include trouble sleeping and unusual dreams.

---

Q: Does Racol have a warning about driving or operating machinery?

Yes. Regulatory warnings describe avoiding driving or operating heavy machinery until a patient knows how the medicine affects them. This is due to potential side effects such as drowsiness, dizziness, and decreased concentration.

---

Q: What is the risk of an allergic reaction to Racol?

Severe allergic reactions, including anaphylaxis and serious skin reactions (such as blistering or rash), have been reported with the use of the medicine’s components. In the event of signs of an allergic reaction, official guidance indicates the need for immediate medical attention.

---

Q: Is Racol known to interact with herbal supplements?

Official drug interaction sections note that the medicine may interact with certain herbal products, particularly those that affect drug metabolism or serotonin levels, such as St. John's Wort. For most other complementary medicines, official documents indicate there is generally not enough information to confirm safety.

---

Q: How long does Racol stay in your system after you stop taking it?

Pharmacokinetic data indicates that the tramadol component has an elimination half-life of approximately 6.3 hours. The combination medicine is typically eliminated from the system within approximately two days of the last dose.

---

Q: Can Racol cause changes in appetite or weight?

Yes. The official prescribing information lists loss of appetite as a reported side effect. Changes in the stomach or gut, such as nausea, vomiting, or diarrhea, are also commonly reported.

---

Q: Is it necessary to have blood work done while taking Racol?

Regulatory patient information states that monitoring of progress at regular visits may be necessary. This monitoring can include blood and urine tests to check for any unwanted effects and ensure proper use.

---

Q: Is Racol safe to use if I have high blood pressure?

High blood pressure (hypertension) is not listed as a contraindication in official documents. However, the medicine has been linked to changes in blood pressure, including hypotension (low blood pressure), in a small number of patients studied.

---

Q: What should I do if a side effect seems to be getting worse?

Official guidance describes stopping the medicine and seeking medical help immediately if a side effect worsens or if a serious symptom (like trouble breathing or swelling) is experienced. This information is intended to prevent further complications.

---

Q: Is it safe to drink alcohol in moderation while taking Racol?

No. Official regulatory warnings recommend avoiding the consumption of alcoholic beverages during treatment. Alcohol may intensify the Central Nervous System (CNS) depressant effects, which can lead to profound sedation, breathing problems, coma, and death.

---

Q: What does 'contraindicated' mean in the context of Racol?

In the context of drug labeling, the term 'contraindicated' means the medicine must not be used. This is because the official documents indicate that the risk of using the medicine in that specific situation or population is too high.

---

Q: Is there a higher risk of side effects in older patients using Racol?

Yes. Regulatory warnings confirm that the risk of opioid-related adverse effects is increased in older adults. These potential effects include respiratory depression, falls, cognitive impairment, and sedation.

---

Q: Where can I find the official patient information leaflet (PIL) for Racol?

Official consumer information, which serves the same purpose as a Patient Information Leaflet, is publicly available through government drug databases. These sources include the NIH DailyMed Drug Label and the FDA Prescribing Information.

---

Q: What should I do if I think I've taken too much Racol?

Official warnings state that accidental ingestion, especially by a child, can result in a fatal overdose. If an overdose is suspected, regulatory guidance describes seeking emergency medical help at once.

---

Q: Do studies look at the quality of life improvements from Racol?

Studies exploring Racol have examined patient-reported outcomes beyond just pain scores. These measures include scales related to disability and activity levels, which reflect functional status.

---

Q: Is Racol a medication that needs to be tapered off slowly?

Yes. Regulatory warnings indicate that because prolonged use can lead to physical dependence, the dose should be slowly lowered over time (tapering) when stopping the medication. This practice is intended to reduce the risk of withdrawal symptoms.

---

Q: Can Racol make existing mental health conditions worse?

Official labeling notes that the medicine may cause psychic reactions, including mood changes. Warnings also advise of the potential for suicidal thoughts, agitation, or increased depression.

---

Q: Are there warnings about changes in behavior while taking Racol?

Yes. Regulatory warnings note that the medicine may cause certain people to be agitated, irritable, or display other abnormal behaviors. Other reported effects include unusual dreams or hallucinations.

Racol (Tramadol and Acetaminophen) oral tablets must be stored according to regulatory requirements to ensure product integrity and prevent misuse of the opioid component.

Storage Requirements

• Temperature: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Brief excursions are permitted to 15 C to 30 C (59 F to 86 F).
• Protection: The medicine must be protected from moisture and kept in its original, tightly closed container.
• Child Safety: Due to the risk of accidental ingestion, Racol must be securely stored out of the sight and reach of children.

Disposal Instructions

As a controlled substance, the recommended method for disposing of unused or expired Racol is to use a drug take-back program or an authorized collection site. If these options are not immediately available, the tablets must be disposed of immediately by flushing them down the toilet, as advised by regulatory authorities for high-risk opioid-containing products.